

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

**EP 1 219 288 A2**

(12)

**EUROPEAN PATENT APPLICATION**

(43) Date of publication:

03.07.2002 Bulletin 2002/27

(51) Int Cl.7: **A61K 7/48**

(21) Application number: **01310844.4**

(22) Date of filing: **21.12.2001**

(84) Designated Contracting States:

**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE TR**

Designated Extension States:

**AL LT LV MK RO SI**

• **Ganopolsky, Irlina**

**Lawrenceville, NJ 08648 (US)**

• **Lukenbach, Elvin**

**Flemington, NJ 08822 (US)**

• **Skover, Gregory**

**Princeton, NJ 08540 (US)**

(30) Priority: **21.12.2000 US 742622**

(71) Applicant: **Johnson & Johnson Consumer  
Companies, Inc.**

**Skillman, NJ 08558-9418 (US)**

(74) Representative: **Mercer, Christopher Paul et al**

**Carpmaels & Ransford**

**43, Bloomsbury Square**

**London WC1A 2RA (GB)**


(72) Inventors:

• **Cole, Curtis**

**Ringoos, NJ 08551 (US)**

(54) **Treatment for skin**

(57) The invention relates to a topical composition for the treatment of skin comprising an effective amount of a compound of the formula:



wherein W, X, Y and Z are selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>3</sub> alkyl group, C<sub>2</sub>-C<sub>4</sub> alkanol group, wherein at least one of X, Y or Z is a C<sub>2</sub>-C<sub>4</sub> alkanol group bearing at least one hydroxyl group and optionally at least one carboxyl group, and wherein A is a mixture of anionic counterions derived from at least two pharmaceutically acceptable acids and esters thereof; and a cosmetically acceptable carrier.

**EP 1 219 288 A2**

**Description**

**CROSS REFERENCE TO RELATED APPLICATION**

5 [0001] This application claims priority to U.S. Provisional Application Serial No. 60/237,230, filed October 2, 2000, the disclosure of which is hereby incorporated by reference.

**FIELD OF THE INVENTION**

10 [0002] This invention relates to compositions and method for improving skin contour by restoring youthful mechanical properties of the skin. More particularly, it relates to compositions containing at least one alkanolamine salts, and their application to mammalian skin to increase the suppleness and compliance of affected skin areas.

**BACKGROUND OF THE INVENTION**

15 [0003] Human beings have long sought products that can reverse or diminish the effects of aging without cosmetic surgery. The skin is composed primarily of water and as we age it loses its ability to retain water resulting in a surface that is dry and rough. This is not only due to a decrease in the water-retaining capacity of the stratum corneum, a decrease in barrier function and a decrease in the amount of secretion of sebum but also modulation of matrix molecules in the dermis that support epidermis. Matrix molecules comprised of proteins and polysaccharides become more crosslinked. This results in a decrease of water in the dermal compartment consequently producing a stiff, non-compliant structure. Aging of both skin and other tissues is, in part, the result of constant free radical damage leading to decreased cell function and matrix flexibility. In addition, sunlight exposure intensifies and augments the aging process. Extensive sun exposure results in photodamage and is manifested as lines, mottling, discoloration, precancers and cancers.

[0004] In addition to changes on the surface of the skin deeper changes occur in the dermis that effect it's mechanical properties making it more leathery and hardened. Free radical damage induces abnormal interfibrillar crosslink formation. This leads to degradation and atrophy of the matrix. As these crosslinks are formed dermal water is excluded.

30 [0005] Current treatments for these environmental insults include moisturizers, chemical peels, and laser surgery to either hydrate the surface of the skin, enhance epidermal turnover or remove the "hardened" dermal or supportive layers. The more aggressive procedures remove skin tissue and enhance epidermal regeneration and new matrix synthesis thereby restoring some of the original mechanical properties associated with young, undamaged skin.

[0006] Japanese Kokai Patent Application No. 495008 discloses an aging inhibitor effect of ethanolamine derivatives which indicates a preventative activity of aging skin effects. According to this application, the age inhibiting compound can be used as a therapeutic to treat aged skin to improve skin elasticity and wrinkles.

35 [0007] U.S. Patent No. 5,554,647 to Perricone discloses a method for percutaneously treating aging skin using ethanolamine ingredients in a dermatologically acceptable carrier. The ethanolamine is selected from the group consisting of dimethylaminoethanol, monoaminoethanol, choline, serine, acetic acid esters of dimethylaminoethanol, acetic acid esters of monoaminoethanol, para-chlorophenylacetic acid esters of dimethylaminoethanol, para-chlorophenylacetic acid esters of monoaminoethanol, and mixtures thereof. These compounds are hypothesized to treat aging skin via a mechanism of neuromuscular stimulation.

[0008] Not wishing to be bound to this hypothesis, we have additionally discovered that the superficial biomechanical properties of the skin are affected by application of these same compounds restoring youthful firmness resulting in improved facial contours.


45 [0009] Thus, it is an object of this invention to provide topical compositions that can be used to improve facial contours by modulating the skin's biomechanical properties producing more youthful characteristics.

[0010] It is another object of this invention to provide stable topical compositions comprising specific alkanolamine compounds that can be utilized to provide the benefits described above.

50 **SUMMARY OF INVENTION**

[0011] It has been discovered that formulations containing alkanolamine salts, significantly increase skin firmness and make skin contours more visible resulting in a more youthful appearance.

55 [0012] Accordingly, the invention relates to a topical composition for the treatment of skin comprising an effective amount of a compound of the formula:



wherein W, X, Y and Z are selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>3</sub> alkyl group, C<sub>2</sub>-C<sub>4</sub> alkanol group, wherein at least one of X, Y or Z is a C<sub>2</sub>-C<sub>4</sub> alkanol group bearing at least one hydroxyl group and optionally at least one carboxyl group, and wherein A is a mixture of anionic counterions derived from at least two pharmaceutically acceptable acids and esters thereof; and a cosmetically acceptable carrier.

[0013] Preferably, the compositions used in the methods according to the invention have a pH ranging from about 4.5 to about 8.5, more preferably, from about 5.5 to about 8.5, more preferably from about 5.5 to about 7.5

[0014] The invention also relates to methods for the treatment of aging skin, in particular, for increasing the suppleness and/or compliance of mammalian skin, using a topically-applied composition.

## DETAILED DESCRIPTION OF THE INVENTION

[0015] The amount of the alkanolamine salt necessary to reverse or diminish the effects of aging on the skin is not fixed per se, and necessarily is dependent upon the severity and extent of the aged tissue and the concentrations of the ingredients in the formulation put together in association with a dermatologically acceptable carrier.

[0016] Generally, even low concentrations of active ingredients in a carrier will be suitable, requiring only that more frequent topical application be resorted to. As a practical matter, however, to avoid the need for repeated application, it is desirable that the topically applied composition be formulated to contain at least about 1% by weight and most preferably at least about 3% by weight, of alkanolamine salt.

[0017] The alkanolamine salt can be made by techniques known in the art by reacting the desired alkanolamine with an appropriate acid under conditions sufficient to form the salt. The salts can be formed *in situ* or prior to formulating. Generally, when at least one of W, X, Y, or Z is hydrogen the alkanolamine salt can be prepared *in situ*.

[0018] In a preferred embodiment, the alkanolamine salt is an acid salt of monomethylaminoethanol, dimethylaminoethanolamine, trimethylaminoethanol, isopropanolamine, triethanolamine, isopropanoldimethylamine, ethylethanolamine, 2-butanamine, choline, serine, and copolymers thereof.

[0019] Suitable acids for use in the preparation of the alkanolamine salts according to the invention include any organic acid known to be useful in skin care compositions. In a preferred embodiment, at least one of the acids is an alpha hydroxy acid, such as taught for example in U.S. Patent No. 5,856,357, the disclosure of which is hereby incorporated by reference. Particularly preferred is a mixture of at least two of glycolic acid, malic acid and citric acids. In a most preferred embodiment, the acid is a combination of glycolic acid and either malic or citric acid. In situations where pH stability is a particular concern, e.g., long term storage, a particularly preferred embodiment is when the acid is a mixture of citric and glycolic acid. Preferably, the ratio of malic or citric acid to glycolic acid ranges from about 1:1 to about 1:5, more preferably, from about 1:1 to about 1:3.

[0020] Another compound which is advantageously present in the compositions of this invention is tyrosine. Tyrosine may be present in the compositions of this invention in the amount of from about 0.01 to about 5%, more preferably from about 0.04 to about 3% by weight and most preferably about 0.5% by weight, based on the total composition.

[0021] Compositions of the invention are applied in admixture with a dermatologically acceptable carrier or vehicle (e.g., as a lotion, cream, ointment, cleanser, or the like). The carriers should be chosen which can solubilize or disperse the ingredients at the concentrations described above. Topical application is facilitated and, in some cases, additional therapeutic effects are provided as might be brought about, e.g., by moisturizing of the affected skin areas. When a carrier is employed, it is necessary that the carrier be inert in the sense of not bringing about a deactivation of the ethanolamine, and in the sense of not bringing about any adverse effect on the skin to which it is applied.

[0022] Suitable carriers include water, alcohols, oils and the like, chosen for their ability to dissolve or disperse the active ingredients at concentrations of active ingredients most suitable for use in the therapeutic treatment.

[0023] The compositions of this invention should be in the form of topical products that can be applied externally to the skin and can be prepared in accordance with conventional techniques known to those of ordinary skill in the art. The carrier may take a variety of physical forms such as, for example, creams, dressings, gels, lotions, ointments or liquids, including leave-on and rinse-off compositions, as well as incorporated into material carriers such as dry and

wet wipes, puffs, hydro-gel matrixes, or adhesive (or non-adhesive) patches by means known in the art. Preferably, the carrier is a gel or moisturizing lotion, a cooling solution or in the form of a dry or wet wipe. One could also utilize this in a convenient spray applicator.

**[0024]** Typical carriers include lotions containing water and/or alcohols and emollients such as hydrocarbon oils and waxes, silicone oils, hyaluronic acid, vegetable, animal or marine fats or oils, glyceride derivatives, fatty acids or fatty acid esters or alcohols or alcohol ethers, lanolin and derivatives, polyhydric alcohols or esters, wax esters, sterols, phospholipids and the like, and generally also emulsifiers (nonionic, cationic or anionic), although some of the emollients inherently possess emulsifying properties. These same general ingredients can be formulated into a cream rather than a lotion, or into gels, or into solid sticks by utilization of different proportions of the ingredients and/or by inclusion of thickening agents such as gums or other forms of hydrophilic colloids. Such compositions are referred to herein as cosmetically acceptable carriers. Preferably, the carrier should be a gel base formula without lipid materials that would exxacerbate the oiliness of acne prone skin. However, a moisturizer emulsion base may be preferred by individuals that have particularly dry yet skin still suffer from acne lesions.

**[0025]** The topical compositions according to the invention can comprise additional ingredients commonly found in skin care compositions, such as for example, emollients, skin conditioning agents, emulsifying agents, humectants, preservatives, antioxidants, perfumes, chelating agents, etc., provided that they are physically and chemically compatible with the other components of the composition. Notably useful is the incorporation of vitamin A and vitamin A derivatives, including but not restricted to retinol, retinyl palmitate, retinoic acid, retinal, and retinyl propionate.

**[0026]** Examples of suitable preservatives for use in the compositions of the invention include the C<sub>1</sub>-C<sub>4</sub> alkyl parabens and phenoxyethanol. Generally, the preservative is present in an amount ranging from about 0.5 to about 2.0, preferably about 1.0 to about 1.5, weight percent based on the total composition. In a preferred embodiment, the preservative is mixture of from about 0.2 to about 0.5 weight percent methylparaben, from about 0.2 to about 5.0 weight percent propylparaben and from about 0.05 to about 0.10 weight percent butylparaben. A particularly preferred commercially available preservative that may be used in the skin care composition according to this invention is PHENONIP TM which is a practically colorless, viscous, liquid mixture of phenoxyethanol, methylparaben, ethylparaben, propylparaben, and butylparaben available from Nipa Laboratories, Inc., Wilmington, Del.

**[0027]** Preferably, antioxidants should be present in the compositions according to the invention. Suitable antioxidants include butylated hydroxy toluene (BHT), ascorbyl palmitate, butylated hydroanisole (BHA), phenyl- $\alpha$ -naphthylamine, hydroquinone, propyl gallate, nordihydroquaiaretic acid, vitamin E or derivatives of vitamin E, vitamin C and derivatives thereof, calcium pantothenic, green tea extracts and mixed polyphenosis, and mixtures thereof of the above. When utilized the antioxidant can be present in an amount ranging from about 0.02 to about 0.5% by weight, more preferably from about 0.002 to about 0.1% by weight of the total composition.

**[0028]** Emollients which can be included in the compositions of the invention function by their ability to remain on the skin surface or in the stratum corneum to act as lubricants, to reduce flaking, and to improve the skin appearance. Typical emollients include fatty esters, fatty alcohols, mineral oil, polyether siloxane copolymers and the like. Examples of suitable emollients include, but are not limited to, polypropylene glycol ("PPG")-15 stearyl ether, PPG-10 cetyl ether, steareth-10, oleth-8, PPG-4 lauryl ether, vitamin E acetate, PEG-7 glyceryl cocoate, lanolin, cetyl alcohol, octyl hydroxystearate, dimethicone, and combinations thereof. Cetyl alcohol, octyl hydroxystearate, dimethicone, and combinations thereof are preferred. When utilized, the emollient can be present in an amount from about 0.01 to about 5, preferably from about 1 to about 4 percent by weight based on the total composition.

**[0029]** Polyhydric alcohols can be utilized as humectants in the compositions of the invention. The humectants aid in increasing the effectiveness of the emollient, reduce scaling, stimulate removal of built-up scale and improve skin feel. Suitable polyhydric alcohols include, but are not limited to, glycerol (also known as glycerin), polyalkylene glycols, alkylene polyols and their derivatives, including butylene glycol, propylene glycol, dipropylene glycol, polypropylene glycol, polyethylene glycol and derivatives thereof, sorbitol, hydroxypropyl sorbitol, hexylene glycol, 1,3-dibutylene glycol, 1,2,6,-hexanetriol, ethoxylated glycerol, propoxylated glycerol and mixtures thereof. Glycerin is preferred. When utilized, the humectant is present in an amount from about 0.1 to about 5, preferably from about 1 to about 3 percent by weight, based on the total weight of the composition.

**[0030]** The compositions according to the invention preferably contain an effective stabilizing amount of an emulsifier. Preferably, the emulsifier is present at from about 1.0 to about 10.0, more preferably from about 3.0 to about 6.0, weight percent, based on the total composition. Any emulsifier that is compatible with the components of the composition can be employed. Suitable emulsifiers include stearic acid, cetyl alcohol, stearyl alcohol, steareth 2, steareth 20, Acrylates/C10-30 alkyl Acrylate Crosspolymer. Particularly preferred is PEMULEN TR-1 (CTFA Designation: Acrylates/10-30 Alkyl Acrylate Crosspolymer).

**[0031]** Any fragrance may be added to the compositions of the invention for aesthetic purposes. Suitable fragrances include, but are not limited to, eucalyptus oil, camphor synthetic, peppermint oil, clove oil, lavender, chamomile and the like. When utilized, fragrances are present in an amount from about 0.05 to about 0.5, preferably from about 0.1 to about 0.3 percent by weight, based on the total weight of the composition. In certain aspects of this invention, the

compositions should include a chelating agent. Chelating agents which are useful in the compositions of the present invention include ethylenediamine tetra acetic acid (EDTA) and derivatives and salts thereof, dihydroxyethyl glycine, tartaric acid, and mixtures thereof. The chelating agents should be utilized in a stabilizing effective amount and may range from about 0.01 to about 2% based on the weight of the total composition, preferably from about 0.05 to about 1%. Most preferably, the chelating agent should be EDTA.

[0032] Generally, the composition is topically applied to the affected skin areas in a predetermined or as-needed regimen to bring about improvement, it generally being the case that gradual improvement is noted with each successive application. Insofar as has been determined based upon clinical studies to date, no adverse side effects are encountered.

[0033] While not wishing to be bound to any theory, it is proposed that treatment in accordance with the present invention may induce changes in the skin permitting a repartitioning of water in cellular membranes as well as dermal matrix molecules. Rather than water being excluded from the dermis the composition may enhance the inclusion of water from the blood. Enhancing water retention in the dermal tissue increases firmness resulting in more improved facial contours visualized as a more youthful appearance.

[0034] The advantages of the invention and specific embodiments of the skin care compositions prepared in accordance with the present invention are illustrated by the following examples. It will be understood, however, that the invention is not confined to the specific limitations set forth in the individual examples, but rather to the scope of the appended claims.

[0035] The following materials were used in the Examples that follow:

AMPHISOL A: cetyl palmitate thickener commercially available from Gattefosse.

AMIGEL: sclerotium gum thickener commercially available from Alban Muller

AMIPHISOL A: cetyl phosphate emulsifying agent commercially available from Givaudan Roche.

BIOSIL BASICS SPQ: silicone quaternium-13 slip/conditioning agent commercially available from Biosil Technologies, Inc.

BRIJ 72: steareth 2 emulsifier commercially available from Uniqema.

BRIJ 721: steareth 20 emulsifier commercially available from Uniqema.

CETIOL SN DEO: cetearyl isononanoate emollient commercially available from Sidobre Sinnova.

CARBOPOL EDT 2020: acrylic acid C10/C30 alkyl acrylate crosspolymer commercially available from BF Goodrich.

CRODESTA SL-40: sucrose cocate skin conditioning agent commercially available from Croda Oleochemicals.

DIMETHICONE 47V-100: dimethicone 100 centistokes emollient commercially available from Rhodia.

DUB LIQUIDE: 90% cetearyl octanoate/10% isopropyl myristate emollient.

FINSOLV TN: C<sub>12</sub>-C<sub>15</sub> alkyl benzoate solubilizing agent commercially available from Finetex.

FUCOGEL 1000R: 2% aqueous solution of biosaccharide gum-1 skin conditioning agent commercially available from Solabia.

GLYCEROL 767: PEG-6 capric/caprylic glycerides commercially available from Croda.

GLYPURE: 70% aqueous solution of glycolic acid commercially available from Clariant

LANETTE 16: cetyl alcohol emollient/emulsifier commercially available from Sidobre Sinnova.

LAMEFORM TGI FL: polyglyceryl-3-diisostearate emulsifying agent commercially available from Sidobre Sinnova.

LUBRAJEL: humectant comprising a mixture of 32% water; 67% glyceryl polymethacrylate, 67% propylene glycol commercially available from Black.

MIRASIL CM5: cyclomethicone skin conditioning agent commercially available from SACI

MIRASIL DM 100: dimethicone skin conditioning agent commercially available from SACI

ORGANOSAL 2002D NATCOS: nylon 12 matifying agent commercially available from Atochem

PEMULEN TR1: acrylates/10-30 alkyl acrylate crosspolymer commercially available from BFGoodrich.

PHENONIP: mixture of phenoxyethanol, methylparaben, ethylparaben, propylparaben, and butylparaben commercially available from Nipa Laboratories, Inc

POLYSYNLANE: hydrogenated polyisobutene skin conditioning agent commercially available from Rossow.

PRICERINE 9091: glycerine humectant commercially available from Uniqema

SP-10: nylon-12 commercially available from Kobo Products.

STABILIEZE QM: PVM/MA decadiene crosspolymer commercially available from ISP Technologies.

WICKENOL 171: octyl hydroxystearate emollient commercially available from Alzo Inc.

WINDSOR TALC 66: talc commercially available from Luzenac/Royston.

#### EXAMPLE 1

[0036] The following formula was made in accordance with the teachings of this invention. Deionized water and

## EP 1 219 288 A2

sodium hydroxide were added to a kettle followed by Lubragel with continuous mixing. The mixture was heated to 50°C with stirring. Then, L-tyrosine was added and the mixture was heated to 80-85°C. In a separate container DUB LIQUIDE, cetyl palmitate, LANETTE 16, MIRACIL CM5, LAMEFORM TGI FL, tocopheryl acetate, phenoxyethanol, methylparaben, propylparaben were mixed and heated until homogeneous. Then AMPHISOL A was added and the whole mixture was heated to 90°C. When, both kettles were at the desired temperatures, oil phase was added to the water phase at 80-85°C with mixing. CETIOL SN DEO and CARBOPOL EDT 2020 were premixed and added to the main kettle. The heat was discontinued and the kettle was kept under stirring while cooling. At 30°C or below the DMAE/glycolic acid/citric acid/water premix was added to the kettle. The pH of the product was adjusted followed by the Perfume IFF FBD 6162 addition. The specific ingredients and weight percentages thereof are tabulated below.

INGREDIENT:	WEIGHT PERCENT:
Deionized water	53.9
Sodium hydroxide	0.20
LUBRAJEL	5.00
L-tyrosine	0.50
DUB LIQUIDE	8.00
Phenoxyethanol	0.50
Methylparaben	0.20
Propylparaben	0.06
Cetyl palmitate	4.00
LANETTE 16	1.50
MIRASIL CM5	0.5
LAMEFORM TGI FL	1.00
Tocopheryl acetate	1.00
AMPHISOL A	1.88
CETIOL SN DEO	6.0
CARBOPOL EDT 2020	0.50
Perfume IFF FBD 6162	0.60
<b>DMAE Premix:</b>	
Deionized water	9.0
DMAE	3.0
<b>Buffer Premix:</b>	
Glycolic acid (70%)/water (30%)	2.19
Citric acid	0.51

### EXAMPLE 2

[0037] The following formula was made in accordance with the teachings of this invention. Deionized water and sodium hydroxide were mixed in the main kettle. When homogeneous, PRICERINE 9091 and Lubragel were added. The mixture was heated to 50°C. Then, ORGANOSAL 2002D NATCOS and L-tyrosine were added and the mixture was kept under stirring for 15 minutes. In a separate container CARBOPOL EOT 2020, AMIGEL, POLYSYNLANE and MIRASIL CM5 were mixed and then added to the main kettle. When the mixture in the kettle was homogeneous, butylene glycol, phenoxyethanol, methylparaben and propylparaben were added. The heating was discontinued, the mixture was mixed for 15 minutes and then, FUCOGEL 1000R was added. The kettle was cooled to 30°C or below and the pre-mix of DMAE, water, citric acid and glycolic acid was added. The pH of the product was adjusted and at the end the fragrance was added. The specific ingredients and weight percentages thereof are tabulated below.

# EP 1 219 288 A2

INGREDIENT:	WEIGHT PERCENT:
Deionized water	65.62
Sodium hydroxide	0.10
L-tyrosine	3.00
ORGANOSAL 2002D NATCOS	0.50
PRICERINE 9091	2.00
LUBRAJEL	3.00
CARBOPOL ETD 2020	0.50
AMIGEL	0.80
POLYSYNLANE	2.00
MIRASIL CM5	4.00
Butylene glycol	4.00
Phenoxyethanol	0.37
Methylparaben	0.10
Propylparaben	0.03
FUCOGEL 1000R	2.00
Perfume IFF FBD 6162	0.20
<b>DMAE Premix:</b>	
Deionized water	10.0
DMAE	1.0
<b>Buffer Premix:</b>	
Glycolic acid (70%)/water (30%)	0.46
Citric acid	0.32

## Example 3

[0038] The following formula was made in accordance with the teachings of this invention. In the main kettle Deionized water and sodium hydroxide were mixed when homogeneous, PRICERINE 9091 and LUBRAJEL were added. The mixture was heated to 50°C, then, ORGANOSAL 2002D NATCOS and L-Tyrosine were added. In a separate container CARBOPOL EDT 2020, AMIGEL and MIRASIL CM5 were pre-mixed and added to the batch. When the mixture in the kettle was homogeneous, Butylene Glycol, Phenoxyethanol, Methylparaben and Propylparaben were added to it. The heating was discontinued and the mixing was kept for 15 minutes, then, FUCOGEL 1000R was added. At 30°C or below the pre-mix of DMAE, water, citric acid and glycolic acid was added to the batch. The pH of the batch was adjusted and the Perfume IFF FBD 6162 was added. The formulation had an initial pH of 6.7 at 25°C. After 24 hours the pH remained 6.7 at 25°C. The specific ingredients and weight percentages thereof are tabulated below.

INGREDIENT:	WEIGHT PERCENT:
Deionized water	66.0
Sodium hydroxide	0.10
L-tyrosine	0.50
ORGANOSAL 2002D NATCOS	0.25
PRICERINE 9091	2.00
LUBRAJEL	3.00

# EP 1 219 288 A2

(continued)

INGREDIENT:	WEIGHT PERCENT:
CARBOPOL ETD 2020	0.50
AMIGEL	0.80
MIRASIL CM5	4.00
Butylene glycol	4.00
Phenoxyethanol	0.37
Methylparaben	0.10
Propylparaben	0.03
FUCOGEL 1000R	2.00
Perfume IFF FBD 6162	0.20
<b>DMAE Premix:</b>	
Deionized water	10.0
DMAE	3.0
<b>Buffer Premix:</b>	
Glycolic acid (70%)/water (30%)	1.6
Citric acid	1.20

## EXAMPLE 4

[0039] The following formula was made in accordance with the teachings of this invention. Deionized water was added to a kettle and heated to about 78 to about 80°C. At about 78 to about 80°C, STABILEZE QM was added using a propeller mixer. The mixture was held at about 78 to about 80°C until clear. Heating was discontinued and when the mixture was at about 75°C, disodium EDTA, CRODESTA SL-40, GLYCEROL 767, and hexylene glycol were added. At about 40°C, the tyrosine/DMAE premix was added to the mixture and mixed well. The DMAE/tyrosine premix was prepared as follows: deionized water, DMAE, and tyrosine were added to a closed container and placed in a heated (50-50°C) water bath. The mixture was heated to about 50 to about 55°C. The mixture was held at that temperature with mixing until the tyrosine dissolved.

[0040] The pH of the mixture was adjusted to about 7.0 to about 7.5 with the glycolic/citric buffer premix. The remaining ingredients were added with mixing in the following order: SP-10, talc, BIOSIL BASICS SPQ, ethanol, PHE-NONIP, and deionized water. The mixture was homogenized at 40% for about 3-4 minutes with a rotor-stator homogenizer.

INGREDIENT:	WEIGHT PERCENT:
Deionized water	54.06
STABILEZE QM	1.50
Disodium EDTA	0.10
CRODESTA SL-40	0.75
GLYCEROL 767	0.75
Hexylene glycol	1.00
<b>DMAE/Tyrosine Premix:</b>	
DMAE	3.00
Deionized water	30.00
L-tyrosine	0.50



# EP 1 219 288 A2

(continued)

INGREDIENT:	WEIGHT PERCENT:
<b>Buffer Premix:</b>	
GLYPURE	2.30
Citric acid	0.80
Deionized water	1.24
<b>Post Addition:</b>	
WINDSOR Talc 66	0.50
SP-10	1.00
BIOSIL Basics SPQ	1.00
Ethanol	0.50
Phenonip	1.00

## EXAMPLE 5

[0041] The following formula was made in accordance with the teachings of this invention. Deionized water was added to a kettle and heated to about 78 to about 82°C. At about 78 to about 82°C, STABILEZE QM was added using a propeller mixer. The mixture was held at about 78 to about 80°C until clear. Heating was discontinued and the mixture was cooled to about 75°C, disodium EDTA, CRODESTA SL-40, GLYCEROL 767, and hexylene glycol were added. At about room temperature, the DMAE premix was added to the mixture and mixed well. The tyrosine premix was prepared as follows: deionized water and urea were added to a closed container and mixed. After the urea was solubilized, L-tyrosine was added to the mixture with mixing. The mixture was mixed until added to the formulation.

[0042] The pH of the mixture was adjusted to about 6.5 to about 7.0 with the glycolic/citric buffer premix. The remaining ingredients were added with mixing in the following order: SP-10, talc, BIOSIL BASICS SPQ, ethanol, PHE-NONIP, and deionized water. The mixture was homogenized at 40% for about 2 minutes with a rotor-stator homogenizer.

INGREDIENT:	WEIGHT PERCENT:
Deionized water	62.59
STABILEZE QM	1.50
Disodium EDTA	0.10
CRODESTA SL-40	0.75
GLYCEROL 767	0.75
Hexylene glycol	1.00
<b>DMAE Premix:</b>	
DMAE	3.00
Deionized water	3.00
<b>Tyrosine/Urea Premix:</b>	
Deionized water	10.00
Urea	5.00
L-tyrosine	5.00
<b>Buffer Premix:</b>	
GLYPURE 70	2.61
Citric acid	0.70
<b>Post Addition:</b>	

## EP 1 219 288 A2

(continued)

INGREDIENT:	WEIGHT PERCENT:
WINDSOR Talc 66	0.50
SP-10	1.00
BIOSIL Basics SPQ	1.00
Ethanol	0.50
PHENONIP	1.00

### EXAMPLE 6

[0043] The following formula was made in accordance with the following procedure. Deionized water was added to a kettle and heated to about 78 to about 80°C. At about 78 to about 80°C, STABILEZE QM was added using a propeller mixer. The mixture was held at about 78 to about 80°C until uniform. Heating was discontinued and when the mixture was at about 75°C, disodium EDTA, CRODESTA SL-40, GLYCEROL 767, and hexylene glycol were added. At about room temperature, the tyrosine/DMAE premix was added to the mixture and mixed well. The DMAE/tyrosine premix was prepared as follows: deionized water, DMAE and tyrosine were added to a closed container and placed in a heated (50-55°C) water bath. The mixture was heated to about 50 to about 55°C. The mixture was held at that temperature with mixing until the tyrosine dissolved.

[0044] The pH of the mixture was adjusted to about 7.0 to about 7.5 with the glycolic/malic buffer premix. The remaining ingredients were added with mixing in the following order: SP-10 talc, BIOSIL BASICS SPQ, ethanol, PHENONIP, and deionized water. The mixture was homogenized at 40% for about 3-4 minutes with a rotor-stator homogenizer. The specific ingredients and proportions thereof are tabulated below.

INGREDIENT:	WEIGHT PERCENT:
Deionized water	55.16
STABILEZE QM	1.50
Disodium EDTA	0.10
CRODESTA SL-40	0.75
Glycerol 767	0.75
Hexylene glycol	1.00
<b>DMAE/Tyrosine Premix:</b>	
DMAE	3.00
Deionized water	30.00
L-tyrosine	0.50
<b>Buffer Premix:</b>	
Glypure	1.20
Malic acid	0.80
Deionized water	1.24
<b>Post Addition:</b>	
Winnor Talc 66	0.50
SP-10	1.00
BIOSIL Basics SPQ	1.00
Ethanol	0.50
Phenonip	1.00

## EP 1 219 288 A2

### EXAMPLE 7

[0045] The following formula was made according to the following procedure: Deionized water was added to a kettle and heated to about 78 to about 80°C. At about 78 to about 82°C, STABILEZE QM was added using a propeller mixer. The mixture was held at about 78 to about 82°C until clear. Heating was discontinued and when the mixture was at about 75°C, disodium EDTA, CRODESTA SL-40, GLYCEROL 767, and hexylene glycol were added. At room temperature, the DMAE premix was added to the mixture to neutralize the STABILEZE followed by the tyrosine premix and mixed well. The pH of the mixture was adjusted to about 6.5 to about 7.0 with glycolic acid. The remaining ingredients were added with mixing in the following order: SD-10, talc, BIOSIL BASICS SPQ, ethanol, PHENONIP, and deionized water. The mixture was homogenized at 40% for about 2 minutes with a rotor-stator homogenizer.

INGREDIENT:	WEIGHT PERCENT:
Deionized water	63.3
STABILEZE QM	1.50
Disodium EDTA	0.10
CRODESTA SL-40	0.75
GLYCEROL 767	0.75
Hexylene glycol	1.00
<b>DMAE Premix:</b>	
DMAE	3.00
Deionized water	3.00
<b>Tyrosine/Urea Premix:</b>	
Deionized water	10.00
Urea	5.00
L-tyrosine	5.00
<b>Post Addition:</b>	
GLYPURE	2.61
Windsor Talc 66	0.50
SP-10	1.00
BIOSIL Basics SPQ	1.00
Ethanol	0.50
PHENONIP	1.00

### EXAMPLE 8

[0046] Examples 1 and 2 were evaluated on panels of 140 consumers in a four-week test. As show by the table below, consumers recognized improvements in skin firmness, less sagging, tightening of the skin, improved facial shape and contours.

Benefits	Example 1	Example 2
Helps skin look firmer under eyes	66*	69
Helps your skin look firmer	66	71
Visibly improves skin appearance	70	74
Firms your skin all day	62	72
Defines and reshapes the contours of your face	43	45

\*Percentage of consumers agreeing with statement

# EP 1 219 288 A2

(continued)

Benefits	Example 1	Example 2
Visibly reduces the appearance of sagging skin	50	60
Lifts your facial skin	51	58
Visibly re-tightens your skin	57	65

## EXAMPLE 9

[0047] This example illustrates the improved pH stability of compositions containing a combination of citric and glycolic acid.


Example	Buffer Type	pH drop
Example 5	Glycolic/citric acid	0.1
Example 6	Glycolic/malic	0.4
Example 8	Glycolic acid	0.4

[0048] Having described the invention with reference to particular compositions, theories of effectiveness, and the like, it will be apparent to those of skill in the art that it is not intended that the invention be limited by such illustrative embodiments or mechanisms, and that modifications can be made without departing from the scope or spirit of the invention, as defined by the appended claims. The claims are meant to cover the claimed components and steps in any sequence which is effective to meet the objectives there intended, unless the context specifically indicates the contrary.

## Claims

1. A composition for use in improving skin firmness, in improving the appearance of facial contours or in reducing the appearance of sagging skin by topical application comprising:

(a) an effective amount of a compound of the formula:



wherein W, X, Y and Z are selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>3</sub> alkyl group, C<sub>2</sub>-C<sub>4</sub> alkanol group, wherein at least one of X, Y or Z is a C<sub>2</sub>-C<sub>4</sub> alkanol group bearing at least one hydroxyl group and optionally at least one carboxyl group, and wherein A is a mixture of anionic counterions derived from at least two pharmaceutically acceptable acids and esters thereof; and

(b) a cosmetically acceptable carrier.

2. The composition of claim 1, wherein at least one of said acids is an alpha hydroxy acid.
3. The composition of claim 1 or claim 2, wherein said acids are selected from glycolic acid, citric acid, malic acid, and mixtures thereof.

**EP 1 219 288 A2**

4. The composition of any one of claims 1 to 3, wherein said anionic counterion is derived from a mixture of glycolic acid and citric acid.
5. The composition of claim 4, wherein the ratio of citric acid to glycolic acid ranges from 1:1 to 1:5.
6. The composition of any one of claims 1 to 3, wherein said anionic counterion is derived from a mixture of glycolic acid and malic acid.
7. The composition of claim 6, wherein the ratio of malic acid to glycolic acid ranges from 1:1 to 1:5.
8. The composition of any one of claims 1 to 7, wherein the pH of said composition ranges from 4.5 to 8.5.
9. The composition of any one of claims 1 to 8, wherein said compound is present at about 10% by weight.
10. The composition of any one of claims 1 to 9, wherein said composition is incorporated into a material carrier selected from a dry wipe, a wet wipe, a puff, a hydrogel matrix, an adhesive patch, or a non-adhesive patch.

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

**EP 1 219 288 A3**

(12)

**EUROPEAN PATENT APPLICATION**

(88) Date of publication A3:  
30.07.2003 Bulletin 2003/31

(51) Int Cl.7: **A61K 7/48**

(43) Date of publication A2:  
03.07.2002 Bulletin 2002/27

(21) Application number: **01310844.4**

(22) Date of filing: **21.12.2001**

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE TR**  
Designated Extension States:  
**AL LT LV MK RO SI**

- **Ganopolsky, Irina**  
Lawrenceville, NJ 08648 (US)
- **Lukenbach, Elvin**  
Flemington, NJ 08822 (US)
- **Skover, Gregory**  
Princeton, NJ 08540 (US)

(30) Priority: **21.12.2000 US 742622**


(71) Applicant: **Johnson & Johnson Consumer  
Companies, Inc.**  
Skillman, NJ 08558-9418 (US)

(74) Representative: **Mercer, Christopher Paul et al**  
**Carpmaels & Ransford**  
43, Bloomsbury Square  
London WC1A 2RA (GB)

(72) Inventors:  
• **Cole, Curtis**  
Ringoos, NJ 08551 (US)

(54) **Treatment for skin**

(57) The invention relates to a topical composition for the treatment of skin comprising an effective amount of a compound of the formula:



wherein W, X, Y and Z are selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>3</sub> alkyl group, C<sub>2</sub>-C<sub>4</sub> alkanol group, wherein at least one of X, Y or Z is a C<sub>2</sub>-C<sub>4</sub> alkanol group bearing at least one hydroxyl group and optionally at least one carboxyl group, and wherein A is a mixture of anionic counterions derived from at least two pharmaceutically acceptable acids and esters thereof; and a cosmetically acceptable carrier.

**EP 1 219 288 A3**



European Patent  
Office

# PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 01 31 0844  
shall be considered, for the purposes of subsequent  
proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	US 6 120 779 A (S. NAYAK ET AL) 19 September 2000 (2000-09-19) * the whole document, in particular example 8, claim 11 *	1-3,8-10	A61K7/48
Y	US 4 105 782 A (R.J. YU ET AL) 8 August 1978 (1978-08-08) * the whole document, in particular examples 6-7 *	1-4,8,9	
Y	EP 0 413 528 A (R.J. YU ET AL) 20 February 1991 (1991-02-20) * page 2, lines 31-36 *	1-4,8,9	
A	GB 1 589 224 A (E.J. VAN SCOTT ET AL) 7 May 1981 (1981-05-07) * whole document, in particular example 5 *	1-5,8,9	
A	DE 24 36 467 A (HENKEL & CIE GMBH) 12 February 1976 (1976-02-12) * pages 2-4; claims *	1,2,8	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			A61K A61Q
<b>INCOMPLETE SEARCH</b> <p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>see sheet C</p>			
Place of search		Date of completion of the search	Examiner
BERLIN		4 June 2003	Van Amsterdam, L
<b>CATEGORY OF CITED DOCUMENTS</b> <p>X : particularly relevant if taken alone  Y : particularly relevant if combined with another document of the same category  A : technological background  O : non-written disclosure  P : intermediate document</p> <p>T : theory or principle underlying the invention  E : earlier patent document, but published on, or after the filing date  D : document cited in the application  L : document cited for other reasons  &amp; : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03/82 (P4/C07)



European Patent  
Office

INCOMPLETE SEARCH  
SHEET C

Application Number  
EP 01 31 0844

Claim(s) searched completely:  
2-7

Claim(s) searched incompletely:  
1,8-10

Reason for the limitation of the search:

Present claim 1 relates to an extremely large number of possible compositions. Support within the meaning of Article 84 EPC and/or disclosure within the meaning of Article 83 EPC is to be found, however, for only a very small proportion of the compositions claimed. In the present case, the claim so lacks support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be sufficiently supported and disclosed, namely those parts relating to compositions as claimed in claim 2.



EP 1 219 288 A3



European Patent  
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number  
EP 01 31 0844

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
A	WO 98 40063 A (JAME FINE CHEMICALS INC) 17 September 1998 (1998-09-17) * the whole document * -----	1,2	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)

EPO FORM 1503 01.92 (P04C10)

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 31 0844

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

04-06-2003

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
US 6120779	A	19-09-2000	NONE		
US 4105782	A	08-08-1978	US	3988470 A	26-10-1976
EP 413528	A	20-02-1991	US	5091171 A	25-02-1992
			AT	130187 T	15-12-1995
			AU	701962 B2	11-02-1999
			AU	3311095 A	15-02-1996
			AU	660917 B2	13-07-1995
			AU	5913990 A	21-02-1991
			CA	2019273 A1	15-02-1991
			CA	2337750 A1	15-02-1991
			DE	69023574 D1	21-12-1995
			DK	413528 T3	11-03-1996
			EP	0413528 A1	20-02-1991
			EP	0671162 A2	13-09-1995
			ES	2081936 T3	16-03-1996
			GR	3018157 T3	29-02-1996
			MX	9203653 A1	01-09-1992
			US	5702688 A	30-12-1997
			US	6060512 A	09-05-2000
			US	5547988 A	20-08-1996
			US	5827882 A	27-10-1998
			US	5670542 A	23-09-1997
			US	5674899 A	07-10-1997
			US	5643961 A	01-07-1997
			US	5648395 A	15-07-1997
			US	5643962 A	01-07-1997
			US	5643952 A	01-07-1997
			US	5656665 A	12-08-1997
			US	5677339 A	14-10-1997
			US	5650436 A	22-07-1997
			US	5637615 A	10-06-1997
			US	5643953 A	01-07-1997
			US	5654340 A	05-08-1997
			US	5677340 A	14-10-1997
			US	5674903 A	07-10-1997
			US	5716992 A	10-02-1998
			US	5648391 A	15-07-1997
			US	5652267 A	29-07-1997
			US	5650437 A	22-07-1997
			US	5656666 A	12-08-1997
			US	5648388 A	15-07-1997
			US	5650440 A	22-07-1997
			US	5670543 A	23-09-1997
			US	5643963 A	01-07-1997

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 31 0844

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

04-06-2003

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 413528	A		US 5690967 A	25-11-1997
			US 5684044 A	04-11-1997
			US 5681853 A	28-10-1997
			US 5561158 A	01-10-1996
			US 5554597 A	10-09-1996
			US 5834510 A	10-11-1998
			US 5942250 A	24-08-1999
			US 5654336 A	05-08-1997
GB 1589224	A	07-05-1981	AU 519802 B2	24-12-1981
			AU 2858377 A	15-03-1979
			BE 858404 A1	06-03-1978
			CA 1115211 A1	29-12-1981
			CY 1245 A	29-06-1984
			DE 2740349 A1	09-03-1978
			FR 2363326 A1	31-03-1978
			FR 2422398 A1	09-11-1979
			HK 46285 A	21-06-1985
			JP 1613451 C	15-08-1991
			JP 2031053 B	11-07-1990
			JP 53096329 A	23-08-1978
			KE 3401 A	08-06-1984
			MY 56685 A	31-12-1985
			PH 13782 A	26-09-1980
			PT 67007 A ,B	01-10-1977
			SG 27584 G	04-01-1985
			US 4363815 A	14-12-1982
			ZA 7705363 A	26-07-1978
DE 2436467	A	12-02-1976	DE 2436467 A1	12-02-1976
WO 9840063	A	17-09-1998	WO 9840063 A1	17-09-1998

EPO FORM P469

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82